NasdaqGM:APM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Aptorum Group Limited, a pharmaceutical company, engages in developing and commercializing novel therapeutics to tackle unmet medical needs. More Details


Snowflake Analysis

Fair value with mediocre balance sheet.

Share Price & News

How has Aptorum Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: APM's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.0%

APM

6.7%

US Biotechs

0.09%

US Market


1 Year Return

-89.9%

APM

31.2%

US Biotechs

12.6%

US Market

Return vs Industry: APM underperformed the US Biotechs industry which returned 30.5% over the past year.

Return vs Market: APM underperformed the US Market which returned 13.6% over the past year.


Shareholder returns

APMIndustryMarket
7 Day-4.0%6.7%0.09%
30 Day-46.9%1.4%-1.6%
90 Day-60.3%-1.2%7.9%
1 Year-89.9%-89.9%33.4%31.2%15.2%12.6%
3 Yearn/a17.9%12.2%38.9%29.6%
5 Yearn/a19.6%11.4%87.6%66.5%

Price Volatility Vs. Market

How volatile is Aptorum Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Aptorum Group undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: APM ($1.69) is trading below our estimate of fair value ($2388.29)

Significantly Below Fair Value: APM is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: APM is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: APM is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate APM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: APM is good value based on its PB Ratio (2.6x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Aptorum Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

91.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: APM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: APM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: APM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: APM's revenue (99.8% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: APM's revenue (99.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if APM's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Aptorum Group performed over the past 5 years?

-46.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: APM is currently unprofitable.

Growing Profit Margin: APM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: APM is unprofitable, and losses have increased over the past 5 years at a rate of 46.2% per year.

Accelerating Growth: Unable to compare APM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: APM has a negative Return on Equity (-99.67%), as it is currently unprofitable.


Next Steps

Financial Health

How is Aptorum Group's financial position?


Financial Position Analysis

Short Term Liabilities: APM's short term assets ($6.1M) exceed its short term liabilities ($3.1M).

Long Term Liabilities: APM's short term assets ($6.1M) exceed its long term liabilities ($2.7M).


Debt to Equity History and Analysis

Debt Level: APM's debt to equity ratio (13.2%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if APM's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: APM has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: APM has less than a year of cash runway if free cash flow continues to reduce at historical rates of 17.9% each year


Next Steps

Dividend

What is Aptorum Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate APM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate APM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if APM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of APM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Ian Huen (40 yo)

2.92yrs

Tenure

US$592,374

Compensation

Mr. Chung Yuen Huen also known as Ian, is the Founder of Aptorum Group Limited and has been its Chief Executive Officer since October 1, 2017 and serves as its Executive Director. Mr. Huen has been Chairma ...


CEO Compensation Analysis

Compensation vs Market: Ian's total compensation ($USD592.37K) is about average for companies of similar size in the US market ($USD595.72K).

Compensation vs Earnings: Ian's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Chung Yuen Huen
Founder2.92yrsUS$592.37k67.45%
$ 34.6m
Darren Lui
President & Executive Directorno dataUS$540.37k14.77%
$ 7.6m
Sabrina Khan
Chief Financial Officer2.92yrsUS$394.99kno data
Siu-yan Ng
Chief Operating Officer1.42yrsUS$127.74kno data
Clark Cheng
Chief Medical Officer & Executive Directorno dataUS$583.06kno data
Wai Lee
Head of R & D and Chairman of Scientific Advisory Boardno dataUS$522.99kno data

2.8yrs

Average Tenure

39.5yo

Average Age

Experienced Management: APM's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Chung Yuen Huen
Founder2.92yrsUS$592.37k67.45%
$ 34.6m
Darren Lui
President & Executive Directorno dataUS$540.37k14.77%
$ 7.6m
Clark Cheng
Chief Medical Officer & Executive Directorno dataUS$583.06kno data
Wai Lee
Head of R & D and Chairman of Scientific Advisory Boardno dataUS$522.99kno data
Mirko Scherer
Independent Non-Executive Director2.92yrsUS$57.82kno data
Charles Bathurst
Independent Non-Executive Director2.92yrsUS$75.82kno data
Kwei-hang Chan
Member of Scientific Advisory Board1.42yrsUS$120.00kno data
Douglas W. Arner
Independent Non-Executive Director2.42yrsUS$57.82kno data
Justin Wu
Independent Non-Executive Director2.92yrsUS$57.82k0.68%
$ 349.1k

2.9yrs

Average Tenure

51yo

Average Age

Experienced Board: APM's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.7%.


Top Shareholders

Company Information

Aptorum Group Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aptorum Group Limited
  • Ticker: APM
  • Exchange: NasdaqGM
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$51.357m
  • Shares outstanding: 30.39m
  • Website: https://www.aptorumgroup.com

Number of Employees


Location

  • Aptorum Group Limited
  • 17 Hanover Square
  • Mayfair
  • London
  • Greater London
  • W1S 1BN
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
APMNasdaqGM (Nasdaq Global Market)YesClass A Ordinary SharesUSUSDDec 2018
A1VDB (Deutsche Boerse AG)YesClass A Ordinary SharesDEEURDec 2018
APMENXTPA (Euronext Paris)YesClass A Ordinary SharesFREURDec 2018

Biography

Aptorum Group Limited, a pharmaceutical company, engages in developing and commercializing novel therapeutics to tackle unmet medical needs. It is pursuing therapeutic projects in orphan diseases, infectio ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/19 06:26
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.